Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Open-label, Prospective Phase III Clinical Study to Compare Polatuzumab Vedotin Plus Rituximab, Ifosfamide, Carboplatin and Etoposide (Pola-R-ICE) With Rituximab, Ifosfamide, Carboplatin and Etoposide (R-ICE) Alone as Salvage Therapy in Patients With Primary Refractory or Relapsed Diffuse Large B-cell Lymphoma (DLBCL)

Next Previous
X
Search
Trial Profile

Open-label, Prospective Phase III Clinical Study to Compare Polatuzumab Vedotin Plus Rituximab, Ifosfamide, Carboplatin and Etoposide (Pola-R-ICE) With Rituximab, Ifosfamide, Carboplatin and Etoposide (R-ICE) Alone as Salvage Therapy in Patients With Primary Refractory or Relapsed Diffuse Large B-cell Lymphoma (DLBCL)

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 07 Jun 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Carboplatin (Primary) ; Etoposide (Primary) ; Ifosfamide (Primary) ; Polatuzumab vedotin (Primary) ; Rituximab (Primary)
  • Indications B-cell lymphoma; Diffuse large B cell lymphoma; T-cell lymphoma
  • Focus Therapeutic Use
  • Acronyms Pola-R-ICE

    • Most Recent Events

    • 13 Dec 2022 Results (n=41) assessing safety and efficacy of Polatuzumab Vedotin combined with rituximab, ifosfamide, carboplatin, and etoposide in Diffuse Large B-Cell Lymphoma, presented at the 64th American Society of Hematology Annual Meeting and Exposition.
    • 15 Nov 2022 According to a Physician-scientists from Rutgers Cancer Institute of New Jersey and RWJBarnabas Health media release, data from tis study will be presented at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition.
    • 03 May 2021 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top